AU2001275078A1 - Bioconjugates of nanoparticles as radiopharmaceuticals - Google Patents

Bioconjugates of nanoparticles as radiopharmaceuticals

Info

Publication number
AU2001275078A1
AU2001275078A1 AU2001275078A AU7507801A AU2001275078A1 AU 2001275078 A1 AU2001275078 A1 AU 2001275078A1 AU 2001275078 A AU2001275078 A AU 2001275078A AU 7507801 A AU7507801 A AU 7507801A AU 2001275078 A1 AU2001275078 A1 AU 2001275078A1
Authority
AU
Australia
Prior art keywords
bioconjugates
radiopharmaceuticals
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275078A
Inventor
Nicholas A. Kotov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma State University
Original Assignee
Oklahoma State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma State University filed Critical Oklahoma State University
Publication of AU2001275078A1 publication Critical patent/AU2001275078A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • GPHYSICS
    • G02OPTICS
    • G02BOPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/10Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
    • G02B6/12Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
    • G02B2006/12166Manufacturing methods
    • G02B2006/12195Tapering

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2001275078A 2000-06-01 2001-05-31 Bioconjugates of nanoparticles as radiopharmaceuticals Abandoned AU2001275078A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20863100P 2000-06-01 2000-06-01
US60/208,631 2000-06-01
PCT/US2001/017658 WO2001091808A2 (en) 2000-06-01 2001-05-31 Bioconjugates of nanoparticles as radiopharmaceuticals

Publications (1)

Publication Number Publication Date
AU2001275078A1 true AU2001275078A1 (en) 2001-12-11

Family

ID=22775357

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275078A Abandoned AU2001275078A1 (en) 2000-06-01 2001-05-31 Bioconjugates of nanoparticles as radiopharmaceuticals

Country Status (5)

Country Link
US (1) US6689338B2 (en)
EP (1) EP1286705A2 (en)
JP (1) JP2003535063A (en)
AU (1) AU2001275078A1 (en)
WO (1) WO2001091808A2 (en)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050013775A1 (en) * 2000-06-01 2005-01-20 Kotov Nicholas A. Bioconjugates of nanoparticles as radiopharmaceuticals
US6953656B2 (en) * 2000-07-14 2005-10-11 Massachusetts Institute Of Technology Direct, externally imposed control of polypeptides
DE60128924T2 (en) * 2000-08-11 2008-02-14 Ishihara Sangyo Kaisha Ltd. COLLOIDAL METAL SOLUTION, MANUFACTURING METHOD THEREFOR AND COATING MATERIAL CONTAINING THIS SOLUTION
WO2003047633A2 (en) * 2001-12-04 2003-06-12 Nanospectra Biosciences, Inc. Treatment of angiogenesis disorders using targeted nanoparticles
US7311004B2 (en) * 2003-03-10 2007-12-25 Capstan Ag Systems, Inc. Flow control and operation monitoring system for individual spray nozzles
EP1624306A4 (en) * 2003-04-30 2008-12-24 Chengdu Kuachang Medical Ind L Apparatus including nanostructures used for separation or analysis, and the preparation and application thereof
WO2005018681A1 (en) * 2003-06-03 2005-03-03 The Trustees Of The University Of Pennsylvania Nanoradiopharmaceuticals and methods of use
TW593158B (en) * 2003-07-31 2004-06-21 Ind Tech Res Inst Magnetic nanoparticle
US7396589B2 (en) 2003-07-31 2008-07-08 Industrial Technology Research Institute Core-shell magnetic nanoparticles comprising an inner-transition element
WO2005046733A1 (en) * 2003-11-17 2005-05-26 Philips Intellectual Property & Standards Gmbh Contrast agent for medical imaging techniques and usage thereof
WO2005058360A2 (en) * 2003-12-17 2005-06-30 Philips Intellectual Property & Standards Gmbh Radiation therapy and medical imaging using uv emitting nanoparticles
US7846412B2 (en) * 2003-12-22 2010-12-07 Emory University Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof
DE102004011776A1 (en) * 2004-03-09 2005-11-03 Lts Lohmann Therapie-Systeme Ag Carrier system in the form of protein-based nanoparticles for the cell-specific accumulation of pharmaceutically active substances
US20050220714A1 (en) * 2004-04-01 2005-10-06 Susan Kauzlarich Agents for use in magnetic resonance and optical imaging
US8128908B2 (en) * 2004-04-30 2012-03-06 University Of Florida Research Foundation, Inc. Nanoparticles and their use for multifunctional bioimaging
ES2368141T3 (en) * 2004-07-12 2011-11-14 Abb Technology Ag HALF VOLTAGE EMPTY CONTACTOR.
WO2006025592A1 (en) * 2004-08-31 2006-03-09 Oxygenix Co., Ltd. Thin-filmy polymeric structure and method of preparing the same
US7306963B2 (en) 2004-11-30 2007-12-11 Spire Corporation Precision synthesis of quantum dot nanostructures for fluorescent and optoelectronic devices
US7514725B2 (en) * 2004-11-30 2009-04-07 Spire Corporation Nanophotovoltaic devices
US7541028B2 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for monoclonal antibody delivery
KR100663985B1 (en) 2005-01-10 2007-01-03 서경식 Water Soluble Metal Sulfide Quantum Dot Nanocrystal Complex
US7278294B2 (en) * 2005-04-12 2007-10-09 Durham Kenimer Giles System and method for determining atomization characteristics of spray liquids
US8250907B2 (en) * 2005-04-12 2012-08-28 Durham Kenimer Giles System and method for determining atomization characteristics of spray liquids
EP1883819A4 (en) * 2005-05-04 2010-04-21 Agency Science Tech & Res Novel water-soluble nanocrystals comprising a polymeric coating reagent, and methods of preparing the same
US7502665B2 (en) * 2005-05-23 2009-03-10 Capstan Ag Systems, Inc. Networked diagnostic and control system for dispensing apparatus
US9089619B2 (en) * 2005-06-06 2015-07-28 University Of Kentucky Hybrid nanocrystals for treatment and bioimaging of disease
US20060273189A1 (en) 2005-06-07 2006-12-07 Capstan Ag Systems, Inc. Electrically actuated variable pressure control system
JP2008547016A (en) * 2005-06-23 2008-12-25 ギョン・シク・ソ Nanoparticle label, diagnostic method using nanoparticle label, diagnostic kit and diagnostic device
KR100806669B1 (en) * 2005-06-23 2008-02-26 김정환 Nanoparticle-Biological Material Complex
US20070009436A1 (en) * 2005-07-08 2007-01-11 Rondinone Adam J Radionuclide nanoparticles encased by inorganic shell having vector biomolecules attached thereto
GB0514513D0 (en) * 2005-07-15 2005-08-24 Ge Healthcare Ltd Particulate agents
DK1943016T3 (en) 2005-10-14 2012-10-01 Vive Crop Prot Inc Composite nanoparticles, nanoparticles and processes for their preparation
AU2006330627A1 (en) * 2005-12-16 2007-07-05 University Of Kansas Nanoclusters for delivery of therapeutics
WO2007099289A1 (en) * 2006-02-28 2007-09-07 Medical Research Council Targeted iron oxide nanoparticles
ES2553193T3 (en) 2006-10-27 2015-12-04 Shinji Takeoka Polymeric structure similar to a thin film and method to prepare it
EP1920784A1 (en) * 2006-11-13 2008-05-14 Koninklijke Philips Electronics N.V. Radiation sensitizers in ionizing radiation therapy and imaging
CN1975420B (en) * 2006-12-08 2012-05-09 南京航空航天大学 Producing method of functional quantum point used for specific recognizating tumor cell
US20080193766A1 (en) * 2007-02-13 2008-08-14 Northern Nanotechnologies Control of Transport to and from Nanoparticle Surfaces
CN101641367B (en) * 2007-02-13 2014-11-19 维乌作物保护有限公司 Control of transport properties to and from nanoparticle surfaces
KR20090089001A (en) * 2008-02-18 2009-08-21 서경식 Multi-bacteria detection device using quantum dot nanocrystal complex and detection method using it
WO2010042212A2 (en) 2008-10-10 2010-04-15 Dara Biosciences, Inc. Methods for treating or preventing pain using spicamycin derivatives
US8794175B2 (en) * 2008-12-03 2014-08-05 The Regents Of The University Of Michigan Rolling contact layer-by-layer assembly
US8053744B2 (en) * 2009-04-13 2011-11-08 Src, Inc. Location analysis using nucleic acid-labeled tags
US8795783B2 (en) 2009-08-31 2014-08-05 The Regents Of The University Of Michigan Preparation of layer-by-layer materials and coatings from ionic liquids
US8378075B2 (en) * 2009-10-27 2013-02-19 The United States Of America, As Represented By The Secretary Of The Navy Covalent attachment of peptides and biological molecules to luminescent semiconductor nanocrystals
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
KR101590220B1 (en) 2009-12-31 2016-01-29 벤타나 메디컬 시스템즈, 인코포레이티드 Methods for producing uniquely specific nucleic acid probes
EP2539355B1 (en) 2010-02-26 2016-10-05 Ventana Medical Systems, Inc. In-situ hybridization with polytag probes
CA2786853A1 (en) 2010-02-26 2011-09-01 Ventana Medical Systems, Inc. Cytogenic analysis of metaphase chromosomes
US8703493B2 (en) 2010-06-15 2014-04-22 Src, Inc. Location analysis using fire retardant-protected nucleic acid-labeled tags
US8999294B2 (en) * 2010-06-23 2015-04-07 The Board Of Regents Of The University Of Texas System Nanoparticles for use in tumor diagnosis and therapy
US8716027B2 (en) 2010-08-03 2014-05-06 Src, Inc. Nucleic acid-labeled tags associated with odorant
EP2633080B1 (en) 2010-10-29 2018-12-05 President and Fellows of Harvard College Method of detecting targets using fluorescently labelled nucleic acid nanotube probes
CA2825453C (en) 2011-03-14 2016-05-10 Ventana Medical Systems, Inc. A method of analyzing chromosomal translocations and a system therefore
JP5951755B2 (en) 2011-05-04 2016-07-13 エイチティージー モレキュラー ダイアグノスティクス, インコーポレイテッド Improved quantitative nuclease protection assay (qNPA) and quantitative nuclease protection sequencing (qNPS) methods
CN102277157B (en) 2011-05-30 2014-06-11 中国科学院苏州纳米技术与纳米仿生研究所 Near-infrared silver sulphide quantum dot as well as preparation method and application thereof
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
WO2013108126A2 (en) 2012-01-16 2013-07-25 University Of Oslo Methyltransferases and uses thereof
WO2013167387A1 (en) 2012-05-10 2013-11-14 Ventana Medical Systems, Inc. Uniquely specific probes for pten, pik3ca, met, top2a, and mdm2
US11242564B2 (en) 2012-07-12 2022-02-08 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
WO2014048942A1 (en) 2012-09-25 2014-04-03 Ventana Medical Systems, Inc. Probes for pten, pik3ca, met, and top2a, and method for using the probes
CN105531377A (en) * 2013-07-30 2016-04-27 哈佛学院院长及董事 Quantitative dna-based imaging and super-resolution imaging
WO2015036405A1 (en) 2013-09-10 2015-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating basal cell carcinoma
US20160265036A1 (en) 2013-11-05 2016-09-15 Htg Molecular Diagnostics, Inc. Methods for detecting nucleic acids
CA2940118C (en) 2014-02-24 2023-05-23 Ventana Medical Systems, Inc. Automated rna detection using labeled 2'-o-methyl rna oligonucleotide probes and signal amplification systems
JP6679593B2 (en) 2014-09-03 2020-04-15 ジーンセグエス,インコーポレイテッド Therapeutic nanoparticles and related compositions, methods and systems
EP3009147A1 (en) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant glioblastoma
JP2018502567A (en) 2015-01-12 2018-02-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Diagnosis method of pancreatic cancer
EP3332358A4 (en) 2015-08-07 2019-05-29 President and Fellows of Harvard College Super resolution imaging of protein-protein interactions
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
KR20180058759A (en) 2015-09-25 2018-06-01 제트와이 테라퓨틱스 인코포레이티드 Pharmaceutical preparations based on microparticles comprising a polysaccharide-vitamin conjugate
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
CA3004504A1 (en) 2015-11-06 2017-05-11 Ventana Medical Systems, Inc. Tissue homogenisation for representative diagnostics
WO2017081073A1 (en) 2015-11-10 2017-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients with decompensated alcoholic cirrhosis
US10760135B2 (en) 2016-01-13 2020-09-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting pancreatic cancer treatment response
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
WO2017202962A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
JP2019520071A (en) 2016-06-14 2019-07-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Method for predicting treatment response of acute severe colitis
WO2018011107A1 (en) 2016-07-11 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of er-alpha 46 in methods and kits for assessing the status of breast cancer
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2018046736A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
WO2018046738A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
WO2018054960A1 (en) 2016-09-21 2018-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and treating resistance to chemotherapy in npm-alk(+) alcl
EP3515453A1 (en) 2016-09-22 2019-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
WO2018122245A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
WO2018122249A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
WO2018146239A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarker for outcome in aml patients
WO2018162404A1 (en) 2017-03-06 2018-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarker for outcome in aml patients
CN106867506B (en) * 2017-03-07 2020-01-07 重庆高圣生物医药有限责任公司 Near-infrared nano fluorescent probe and preparation method thereof
WO2018172540A1 (en) 2017-03-24 2018-09-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to predict the progression of alzheimer's disease
EP3601613B1 (en) 2017-03-29 2021-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assessing pregnancy outcome
WO2018189215A1 (en) 2017-04-12 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from hepatocellular carcinoma
WO2019038219A1 (en) 2017-08-21 2019-02-28 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method of pancreatic cancer
WO2019043138A1 (en) 2017-09-01 2019-03-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the outcome of a cancer
US11691141B2 (en) 2017-11-13 2023-07-04 Roche Sequencing Solutions, Inc. Devices for sample analysis using epitachophoresis
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
WO2019229489A1 (en) 2018-05-31 2019-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mir-146a-5p and mir-186 as biomarkers of osteoarthritis
WO2020089428A1 (en) 2018-11-02 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method of pancreatic cancer
WO2020089432A1 (en) 2018-11-02 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method of pancreatic cancer
WO2020141199A1 (en) 2019-01-03 2020-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
EP3911669A1 (en) 2019-01-16 2021-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Variants of erythroferrone and their use
EP3924520A1 (en) 2019-02-13 2021-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
WO2020182932A1 (en) 2019-03-13 2020-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) New gene signatures for predicting survival time in patients suffering from renal cell carcinoma
WO2020193740A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
JP2022529917A (en) 2019-04-18 2022-06-27 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods for cancer treatment and prognosis
EP3959340A1 (en) 2019-04-24 2022-03-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Method for predicting the response of antipsychotic drugs
EP3969583A1 (en) 2019-05-14 2022-03-23 F. Hoffmann-La Roche AG Devices and methods for sample analysis
WO2020229521A1 (en) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for inhibiting or reducing bacterial biofilms on a surface
WO2021001539A1 (en) 2019-07-04 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to detect and treat eosinophilic fasciitis
CN110436510B (en) * 2019-08-13 2021-08-10 华中科技大学 Preparation method of water-soluble silver sulfide nanoshell
WO2021044012A1 (en) 2019-09-05 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment and pronostic of acute myeloid leukemia
WO2021063968A1 (en) 2019-09-30 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and composition for diagnosing chronic obstructive pulmonary disease
WO2021074391A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing nasal intestinal type adenocarcinomas
US20230113705A1 (en) 2020-02-28 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
EP4121768A1 (en) 2020-03-20 2023-01-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from a cancer
EP4165214A1 (en) 2020-06-10 2023-04-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Method for treating and prognosing cancer like glioblastoma
WO2021255204A1 (en) 2020-06-18 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2022018163A1 (en) 2020-07-22 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting survival time in patients suffering from cancer
WO2022064049A1 (en) 2020-09-28 2022-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing brucella infection
EP4232603A1 (en) 2020-10-20 2023-08-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Method for predicting the response to tnf inhibitors
CN112305053B (en) * 2020-10-30 2022-12-02 扬州大学 Indium sulfide nanoparticle modified labeled electrochemical immunosensor and electrochemical immunoassay method thereof
CN116917502A (en) 2020-11-06 2023-10-20 Inserm(法国国家健康医学研究院) Methods of diagnosing and treating polycystic ovary syndrome (PCOS)
WO2022136252A1 (en) 2020-12-21 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for prognosis the humoral response of a subject prior to vaccination
WO2022135753A1 (en) 2020-12-21 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for prognosis the humoral response of a subject prior to vaccination
WO2022152698A1 (en) 2021-01-12 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of npdk-d to evaluate cancer prognosis
US20240044901A1 (en) 2021-02-09 2024-02-08 Institut National de la Santé et de la Recherche Médicale New method to pronostic lung cancer
EP4308934A1 (en) 2021-03-17 2024-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing pancreatic cancer
WO2022207566A1 (en) 2021-03-29 2022-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to evaluate pancreatic cancer prognosis
EP4326903A1 (en) 2021-04-23 2024-02-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating cell senescence accumulation related disease
WO2023280790A1 (en) 2021-07-05 2023-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
WO2023089159A1 (en) 2021-11-22 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy targeting stroma/tumor cell crosstalk to treat a cancer
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023152133A1 (en) 2022-02-08 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing colorectal cancer
CN114984213A (en) * 2022-05-30 2022-09-02 华中科技大学 Copper sulfide/bismuth sulfide/diallyl trisulfide nano composite ball and preparation method and application thereof
CN115364248A (en) * 2022-08-16 2022-11-22 天津医科大学总医院 A kind of 131 I-BSA @ CuS nano-particles and preparation method and application thereof
WO2024061930A1 (en) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale New method to treat and diagnose peripheral t-cell lymphoma (ptcl)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
DE4117782C2 (en) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanocrystalline magnetic iron oxide particles, processes for their production and diagnostic and / or therapeutic agents
US5521289A (en) * 1994-07-29 1996-05-28 Nanoprobes, Inc. Small organometallic probes
DE4428851C2 (en) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Nanoparticles containing iron, their production and application in diagnostics and therapy
US5985353A (en) * 1994-12-01 1999-11-16 University Of Massachusetts Lowell Biomolecular synthesis of quantum dot composites
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
ATE261721T1 (en) * 1997-06-13 2004-04-15 Nanopharm Ag SYSTEM FOR THE TARGETED DELIVERY OF ACTIVE INGREDIENTS, METHOD FOR ITS PRODUCTION AND USE
AU3532197A (en) * 1997-07-24 1999-02-16 Australian National University, The Method for detection of fibrin clots
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6207392B1 (en) * 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
DE69921773D1 (en) * 1998-01-16 2004-12-16 Univ Johns Hopkins ORAL ADMINISTRATION OF NUCLEIC ACID VACCINE THROUGH PARTICLE COMPLEXES
US6426513B1 (en) 1998-09-18 2002-07-30 Massachusetts Institute Of Technology Water-soluble thiol-capped nanocrystals
ATE273515T1 (en) 1998-09-18 2004-08-15 Massachusetts Inst Technology WATER SOLUBLE FLUORESCENT SEMICONDUCTOR RNACRYSTALS
US6333110B1 (en) * 1998-11-10 2001-12-25 Bio-Pixels Ltd. Functionalized nanocrystals as visual tissue-specific imaging agents, and methods for fluorescence imaging
US6261779B1 (en) * 1998-11-10 2001-07-17 Bio-Pixels Ltd. Nanocrystals having polynucleotide strands and their use to form dendrimers in a signal amplification system
US6114038A (en) * 1998-11-10 2000-09-05 Biocrystal Ltd. Functionalized nanocrystals and their use in detection systems
US6235540B1 (en) * 1999-03-30 2001-05-22 Coulter International Corp. Semiconductor nanoparticles for analysis of blood cell populations and methods of making same
US6274323B1 (en) * 1999-05-07 2001-08-14 Quantum Dot Corporation Method of detecting an analyte in a sample using semiconductor nanocrystals as a detectable label
CN1379687A (en) * 1999-09-14 2002-11-13 生物医学阿佩则系统有限公司 Magnetic nanoparticles having biochemial activity, method for production thereof and their use
FR2800635B1 (en) * 1999-11-05 2002-07-26 Bio Merieux COMPOSITE NANOSPHERES, DERIVATIVE CONJUGATES, METHOD OF PREPARATION AND USES THEREOF

Also Published As

Publication number Publication date
WO2001091808A2 (en) 2001-12-06
EP1286705A2 (en) 2003-03-05
JP2003535063A (en) 2003-11-25
US6689338B2 (en) 2004-02-10
US20020015679A1 (en) 2002-02-07
WO2001091808A3 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
AU2001275078A1 (en) Bioconjugates of nanoparticles as radiopharmaceuticals
AU2001280138A1 (en) Hard capsule
AU2002313236A1 (en) Medicinal compositions
AU2002355904A1 (en) Perfume-containing composition
AU2001282877A1 (en) Cosmetic compositions
AU2002225855A1 (en) Preparation of nanocrystallites
EP1435894A4 (en) Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
AU2002210993A1 (en) Medicinal compositions for concominant use as anticancer agents
AU2001233691A1 (en) Antiperspirant compositions
AU2001265919A1 (en) Cosmetic compositions
AU2001267707A1 (en) Antiperspirant formulations
AU2002359659A1 (en) Cross reference to related application
AU2001293728A1 (en) Cosmetic composition
AU2002258221A1 (en) Medicinal composition
AU2001285790A1 (en) Antiperspirant compositions
AU2002214324A1 (en) Medicinal compositions
AU2001290239A1 (en) Medicinal composition
AU2001267693A1 (en) Antiperspirant formulations
EP1438003B8 (en) Cosmetic compositions
AU2002302569A1 (en) Antiperspirant formulations
AU2002358649A1 (en) Antiperspirant composition
AU2000274826A1 (en) Cosmetic compositions
AU2001256202A1 (en) Cosmetic compositions
AU2002354460A1 (en) Medicinal composition
AU2002227928A1 (en) Cosmetic composition